Key Highlights

  • 0.95 is the per-share loss behind the consensus EPS forecast of -0.95 for Immunic, Inc. (NASDAQ:IMUX), versus -0.19 for Eledon and Neumora and -0.13 for TuHURA, according to the screener data.
  • 216.97 million is the USD market Capitalization of Eledon Pharmaceuticals (NASDAQ:ELDN) in the screener data, ahead of USD 110.79 million for Immunic, USD 96.86 million for TuHURA and USD 88.87 million for Neumora.
  • 155.1 million is the USD in cash Immunic held on June 30, 2026, compared with USD 116.8 million at Neumora Therapeutics, Inc. (NASDAQ:NMRA), USD 88.8 million at Eledon and a mere USD 1.0 million at TuHURA.
  • 600 patients are slated for Eledon's Phase 3 tegoprubart kidney transplant study, while TuHURA Biosciences, Inc. (NASDAQ:HURA) anticipates finishing Phase 3 enrollment in Merkel cell carcinoma across the back half of 2027.

Eledon Pharmaceuticals (NASDAQ:ELDN): EPS Estimate -0.19, USD 216.97 Million Market Value

Eledon Pharmaceuticals (NASDAQ:ELDN) is the lone name in this group listed for once trading ends on November 13, 2026, with a consensus forecast of a 0.19 per-share loss and a USD 216.97 million valuation, the biggest of the four, in the screener data. Second-quarter net loss reached USD 31.6 million, or 0.27 per share, up from USD 11.2 million and 0.13 in the prior-year period, with a USD 9.6 million non-cash loss from Warrant Fair Value inside it. Spending on Research and Development was USD 18.2 million, against USD 20.3 million. At Eledon Pharmaceuticals (NASDAQ:ELDN), holdings of cash, cash equivalents plus near-term investments totalled USD 88.8 million on June 30, 2026, down from USD 133.3 million on December 31, 2025, which management says funds operations through second-quarter 2027. BESTOW data at 18 months put mean eGFR near 74 against 61 on tacrolimus, and tegoprubart patients recorded zero acute rejection events confirmed by biopsy after six months, against seven on tacrolimus. Liabilities tied to warrants climbed to USD 40.0 million, while no formal financial outlook accompanied the results. The Phase 3 study starts in late 2026 with a 52-week non-inferiority comparison to tacrolimus, and 12 of 12 islet patients became insulin-independent. Common shares outstanding were 80,891,404.

Immunic, Inc. (NASDAQ:IMUX): EPS Estimate -0.95, USD 110.79 Million Market Value

Immunic, Inc. (NASDAQ:IMUX) publishes ahead of the opening bell on November 13, 2026, carrying the deepest per-share loss forecast of these four at -0.95, plus a USD 110.79 million valuation, in the screener data. Second-quarter loss was USD 0.80 for each share, from a net loss near USD 34.1 million, against USD 2.03 and USD 26.8 million a year before. Research and development spending climbed to USD 25.9 million from USD 21.3 million, while overhead spending climbed to USD 9.4 million from USD 5.7 million. At Immunic, Inc. (NASDAQ:IMUX), USD 155.1 million of cash on June 30, 2026 should, according to management, carry operations into late 2027 after a February 2026 private placement. Top-line results from the Phase 3 ENSURE-1 and ENSURE-2 studies in relapsing MS are due by the close of 2026, with a US NDA planned for mid-2027. Operating expenses of USD 35.3 million for the quarter equal roughly 23% of cash, calculated. Product Revenue is absent, and no outlook for revenue or expenses was offered. Weighted-average shares were 42,513,839 versus 13,217,520 one year earlier, which makes dilution a risk, while a Phase 3 study in progressive MS is set to begin later in 2026.

Neumora Therapeutics, Inc. (NASDAQ:NMRA): EPS Estimate -0.19, USD 88.87 Million Market Value

Neumora Therapeutics, Inc. (NASDAQ:NMRA) publishes ahead of the opening bell on November 13, 2026, with a consensus forecast of a 0.19 per-share loss and a USD 88.87 million valuation in the screener data, which falls under USD 100 million, so the Volatility and Liquidity hazards typical of small caps apply. Its net loss for the second quarter was USD 43.1 million, or 0.23 per share, against USD 52.7 million, or 0.33, a year before, as research spending dropped to USD 29.3 million. At Neumora Therapeutics, Inc. (NASDAQ:NMRA), cash of USD 116.8 million on June 30, 2026 fell from USD 182.5 million on December 31, 2025, with management expecting it to cover its operating plan into third-quarter 2027. Cash tops the screener valuation by roughly USD 27.9 million, a calculated gap that is worth noting. Management plans to submit an NMRA-215 IND during fourth-quarter 2026, with NMRA-511 data in fourth-quarter timing and NMRA-898 data in second-half timing for 2026. Joshua Pinto stepped in as president and CEO, and the Leadership transition plus funding needs beyond third-quarter 2027 are risks. Net loss over six months was USD 96.5 million against USD 120.7 million, with weighted-average shares at 185.2 million against 161.7 million.

TuHURA Biosciences, Inc. (NASDAQ:HURA): EPS Estimate -0.13, USD 96.86 Million Market Value

TuHURA Biosciences, Inc. (NASDAQ:HURA) publishes ahead of the opening bell on November 13, 2026, with the mildest loss forecast of the four, -0.13 per share, plus a USD 96.86 million valuation in the screener data, which falls under USD 100 million, so risks tied to small and nano-cap names apply. Second-quarter research and development spending was USD 6.6 million, and overhead spending was USD 2.1 million, against USD 4.9 million and USD 1.9 million one year earlier. At TuHURA Biosciences, Inc. (NASDAQ:HURA), cash was just USD 1.0 million on June 30, 2026, while operating cash burn over six months was USD 13.0 million. The biggest Shareholder offered a USD 50 million Credit Facility meant to stretch the runway into 2028, yet only USD 5.7 million had arrived, at 12% interest and principal due April 21, 2031. Management expects orphan status for IFx-2.0 in second-half 2026 and early investigator-study readouts in first-half 2027. A second-quarter net loss figure did not surface in published reporting, with the timing of its call unconfirmed in the data. Roughly 63.7 million shares stood outstanding on June 30, 2026, while at-the-market sales brought in USD 0.3 million in April plus USD 0.1 million in July. Phase 3 enrollment should wrap up in second-half 2027.

Where Things Stand

Four biotech companies publish on November 13, 2026, with loss forecasts between -0.13 and -0.95 per share. Eledon Pharmaceuticals (NASDAQ:ELDN) publishes once trading ends and points to a runway through second-quarter 2027. Immunic, Inc. (NASDAQ:IMUX) expects ENSURE results by the close of 2026. Neumora Therapeutics, Inc. (NASDAQ:NMRA) has cash stretching into third-quarter 2027 plus several fourth-quarter milestones. TuHURA Biosciences, Inc. (NASDAQ:HURA) leans on drawing its facility, against USD 1.0 million of cash. Funding and timing commentary deserves the closest attention. Readers should view this piece as general information and not as a recommendation to buy or sell.